Pancreatic cancer: Basic and clinical aspects

Gastroenterology

Volumn 128, Issue 6, 2005, Pages 1606-1625

  Schneider, Günter ^a   Siveke, Jens T ^a   Eckel, Florian ^a   Schmid, Roland M ^a,b  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BEVACIZUMAB; CAFFEINE; CAPECITABINE; CELECOXIB; CETUXIMAB; CISPLATIN; CURCUMIN; CYCLOOXYGENASE 2 INHIBITOR; CYTARABINE; DOCETAXEL; ERLOTINIB; EXATECAN; FLUOROURACIL; GEMCITABINE; IRINOTECAN; MARIMASTAT; MATRIX METALLOPROTEINASE INHIBITOR; MITOMYCIN C; OXALIPLATIN; PEMETREXED; TANOMASTAT; TEMSIROLIMUS; TIPIFARNIB; TRANSCRIPTION FACTOR;

APOPTOSIS; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER INHIBITION; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CELL AGING; CLINICAL TRIAL; DRUG TARGETING; GENE MUTATION; HUMAN; NONHUMAN; ONCOGENE; ONCOGENE K RAS; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PANCREAS DUCT; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; TUMOR SUPPRESSOR GENE;

EID: 18844431062     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2005.04.001     Document Type: Article

References (194)

1. A. Jemal, R.C. Tiwari, T. Murray, A. Ghafoor, A. Samuels, E. Ward, E.J. Feuer, M.J. Thun Cancer statistics, 2004 CA Cancer J Clin 54 2004 8 29
2. R.H. Hruban, N.V. Adsay, J. Albores-Saavedra, C. Compton, E.S. Garrett, S.N. Goodman, S.E. Kern, D.S. Klimstra, G. Kloppel, D.S. Longnecker, J. Luttges, G.J. Offerhaus Pancreatic intraepithelial neoplasia a new nomenclature and classification system for pancreatic duct lesions Am J Surg Pathol 25 2001 579 586
3. S.C. Sommers, S.A. Murphy, S. Warren Pancreatic duct hyperplasia and cancer Gastroenterology 27 1954 629 640
4. A.L. Cubilla, P.J. Fitzgerald Morphological patterns of primary nonendocrine human pancreas carcinoma Cancer Res 35 1975 2234 2248
5. A.L. Cubilla, P.J. Fitzgerald Morphological lesions associated with human primary invasive nonendocrine pancreas cancer Cancer Res 36 1976 2690 2698
6. D.S. Klimstra, D.S. Longnecker K-ras mutations in pancreatic ductal proliferative lesions Am J Pathol 145 1994 1547 1550
7. R.H. Hruban, K. Takaori, D.S. Klimstra, N.V. Adsay, J. Albores-Saavedra, A.V. Biankin, S.A. Biankin, C. Compton, N. Fukushima, T. Furukawa, M. Goggins, Y. Kato, G. Kloppel, D.S. Longnecker, J. Luttges, A. Maitra, G.J. Offerhaus, M. Shimizu, S. Yonezawa An illustrated consensus on the classification of pancreatic intraepithelial neoplasia and intraductal papillary mucinous neoplasms Am J Surg Pathol 28 2004 977 987
8. R.H. Hruban, M. Goggins, J. Parsons, S.E. Kern Progression model for pancreatic cancer Clin Cancer Res 6 2000 2969 2972
9. R.H. Hruban, G.M. Petersen, M. Goggins, A.C. Tersmette, G.J. Offerhaus, F. Falatko, C.J. Yeo, S.E. Kern Familial pancreatic cancer Ann Oncol 10 Suppl 4 1999 69 73
10. N. Bardeesy, R.A. DePinho Pancreatic cancer biology and genetics Nat Rev Cancer 2 2002 897 909
11. D.E. Hansel, S.E. Kern, R.H. Hruban Molecular pathogenesis of pancreatic cancer Annu Rev Genomics Hum Genet 4 2003 237 256
12. D. Li, K. Xie, R. Wolff, J.L. Abbruzzese Pancreatic cancer Lancet 363 2004 1049 1057
13. C.A. Schmitt Senescence, apoptosis and therapy--cutting the lifelines of cancer Nat Rev Cancer 3 2003 286 295
14. S.W. Lowe, E. Cepero, G. Evan Intrinsic tumour suppression Nature 432 2004 307 315
15. C. Almoguera, D. Shibata, K. Forrester, J. Martin, N. Arnheim, M. Perucho Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes Cell 53 1988 549 554
16. C. Caldas, S.E. Kern K-ras mutation and pancreatic adenocarcinoma Int J Pancreatol 18 1995 1 6
17. P.G. Terhune, D.M. Phifer, T.D. Tosteson, D.S. Longnecker K-ras mutation in focal proliferative lesions of human pancreas Cancer Epidemiol Biomarkers Prev 7 1998 515 521
18. S.K. Apple, J.R. Hecht, D.N. Lewin, S.A. Jahromi, W.W. Grody, R.K. Nieberg Immunohistochemical evaluation of K-ras, p53, and HER-2/neu expression in hyperplastic, dysplastic, and carcinomatous lesions of the pancreas evidence for multistep carcinogenesis Hum Pathol 30 1999 123 129
19. J.M. Shields, K. Pruitt, A. McFall, A. Shaub, C.J. Der Understanding Ras 'it ain't over 'til it's over' Trends Cell Biol 10 2000 147 154
20. M. Tada, M. Omata, S. Kawai, H. Saisho, M. Ohto, R.K. Saiki, J.J. Sninsky Detection of ras gene mutations in pancreatic juice and peripheral blood of patients with pancreatic adenocarcinoma Cancer Res 53 1993 2472 2474
21. A. Yanagisawa, K. Ohtake, K. Ohashi, M. Hori, T. Kitagawa, H. Sugano, Y. Kato Frequent c-Ki-ras oncogene activation in mucous cell hyperplasias of pancreas suffering from chronic inflammation Cancer Res 53 1993 953 956
22. M. Tada, M. Ohashi, Y. Shiratori, T. Okudaira, Y. Komatsu, T. Kawabe, H. Yoshida, R. Machinami, K. Kishi, M. Omata Analysis of K-ras gene mutation in hyperplastic duct cells of the pancreas without pancreatic disease Gastroenterology 110 1996 227 231
23. C.A. Moskaluk, R.H. Hruban, S.E. Kern p16 and K-ras gene mutations in the intraductal precursors of human pancreatic adenocarcinoma Cancer Res 57 1997 2140 2143
24. F. Ishikawa Cellular senescence, an unpopular yet trustworthy tumor suppressor mechanism Cancer Sci 94 2003 944 947
25. G.P. Dimri, E. Hara, J. Campisi Regulation of two E2F-related genes in presenescent and senescent human fibroblasts J Biol Chem 269 1994 16180 16186
26. G.P. Dimri, X. Lee, G. Basile, M. Acosta, G. Scott, C. Roskelley, E.E. Medrano, M. Linskens, I. Rubelj, O. Pereira-Smith A biomarker that identifies senescent human cells in culture and in aging skin in vivo Proc Natl Acad Sci U S A 92 1995 9363 9367
27. G.P. Dimri, A. Testori, M. Acosta, J. Campisi Replicative senescence, aging and growth-regulatory transcription factors Biol Signals 5 1996 154 162
28. S.W. Lowe, C.J. Sherr Tumor suppression by Ink4a-Arf progress and puzzles Curr Opin Genet Dev 13 2003 77 83
29. M. Serrano, A.W. Lin, M.E. McCurrach, D. Beach, S.W. Lowe Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a Cell 88 1997 593 602
30. T. Kamijo, F. Zindy, M.F. Roussel, D.E. Quelle, J.R. Downing, R.A. Ashmun, G. Grosveld, C.J. Sherr Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF Cell 91 1997 649 659
31. I. Palmero, C. Pantoja, M. Serrano p19ARF links the tumour suppressor p53 to Ras Nature 395 1998 125 126
32. C. Caldas, S.A. Hahn, L.T. da Costa, M.S. Redston, M. Schutte, A.B. Seymour, C.L. Weinstein, R.H. Hruban, C.J. Yeo, S.E. Kern Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma Nat Genet 8 1994 27 32
33. E. Rozenblum, M. Schutte, M. Goggins, S.A. Hahn, S. Panzer, M. Zahurak, S.N. Goodman, T.A. Sohn, R.H. Hruban, C.J. Yeo, S.E. Kern Tumor-suppressive pathways in pancreatic carcinoma Cancer Res 57 1997 1731 1734
34. M. Schutte, R.H. Hruban, J. Geradts, R. Maynard, W. Hilgers, S.K. Rabindran, C.A. Moskaluk, S.A. Hahn, I. Schwarte-Waldhoff, W. Schmiegel, S.B. Baylin, S.E. Kern, J.G. Herman Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas Cancer Res 57 1997 3126 3130
35. R.E. Wilentz, J. Geradts, R. Maynard, G.J. Offerhaus, M. Kang, M. Goggins, C.J. Yeo, S.E. Kern, R.H. Hruban Inactivation of the p16 (INK4A) tumor-suppressor gene in pancreatic duct lesions loss of intranuclear expression Cancer Res 58 1998 4740 4744
36. L. Liu, D. Dilworth, L. Gao, J. Monzon, A. Summers, N. Lassam, D. Hogg Mutation of the CDKN2A 5′ UTR creates an aberrant initiation codon and predisposes to melanoma Nat Genet 21 1999 128 132
37. G. Lal, L. Liu, D. Hogg, N.J. Lassam, M.S. Redston, S. Gallinger Patients with both pancreatic adenocarcinoma and melanoma may harbor germline CDKN2A mutations Genes Chromosomes Cancer 27 2000 358 361
38. J.A. Randerson-Moor, M. Harland, S. Williams, D. Cuthbert-Heavens, E. Sheridan, J. Aveyard, K. Sibley, L. Whitaker, M. Knowles, J.N. Bishop, D.T. Bishop A germline deletion of p14(ARF) but not CDKN2A in a melanoma-neural system tumour syndrome family Hum Mol Genet 10 2001 55 62
39. D.A. Alcorta, Y. Xiong, D. Phelps, G. Hannon, D. Beach, J.C. Barrett Involvement of the cyclin-dependent kinase inhibitor p16 (INK4a) in replicative senescence of normal human fibroblasts Proc Natl Acad Sci U S A 93 1996 13742 13747
40. E. Hara, R. Smith, D. Parry, H. Tahara, S. Stone, G. Peters Regulation of p16CDKN2 expression and its implications for cell immortalization and senescence Mol Cell Biol 16 1996 859 867
41. D. Kato, K. Miyazawa, M. Ruas, M. Starborg, I. Wada, T. Oka, T. Sakai, G. Peters, E. Hara Features of replicative senescence induced by direct addition of antennapedia-p16INK4A fusion protein to human diploid fibroblasts FEBS Lett 427 1998 203 208
42. B.B. McConnell, M. Starborg, S. Brookes, G. Peters Inhibitors of cyclin-dependent kinases induce features of replicative senescence in early passage human diploid fibroblasts Curr Biol 8 1998 351 354
43. A.W. Lin, M. Barradas, J.C. Stone, L. van Aelst, M. Serrano, S.W. Lowe Premature senescence involving p53 and p16 is activated in response to constitutive MEK/MAPK mitogenic signaling Genes Dev 12 1998 3008 3019
44. J. Zhu, D. Woods, M. McMahon, J.M. Bishop Senescence of human fibroblasts induced by oncogenic Raf Genes Dev 12 1998 2997 3007
45. W. Wang, J.X. Chen, R. Liao, Q. Deng, J.J. Zhou, S. Huang, P. Sun Sequential activation of the MEK-extracellular signal-regulated kinase and MKK3/6-p38 mitogen-activated protein kinase pathways mediates oncogenic ras-induced premature senescence Mol Cell Biol 22 2002 3389 3403
46. N. Ohtani, Z. Zebedee, T.J. Huot, J.A. Stinson, M. Sugimoto, Y. Ohashi, A.D. Sharrocks, G. Peters, E. Hara Opposing effects of Ets and Id proteins on p16INK4a expression during cellular senescence Nature 409 2001 1067 1070
47. J.M. Trimarchi, J.A. Lees Sibling rivalry in the E2F family Nat Rev Mol Cell Biol 3 2002 11 20
48. J.H. Dannenberg, A. van Rossum, L. Schuijff, H. te Riele Ablation of the retinoblastoma gene family deregulates G(1) control causing immortalization and increased cell turnover under growth-restricting conditions Genes Dev 14 2000 3051 3064
49. J. Sage, G.J. Mulligan, L.D. Attardi, A. Miller, S. Chen, B. Williams, E. Theodorou, T. Jacks Targeted disruption of the three Rb-related genes leads to loss of G(1) control and immortalization Genes Dev 14 2000 3037 3050
50. J. Sage, A.L. Miller, P.A. Perez-Mancera, J.M. Wysocki, T. Jacks Acute mutation of retinoblastoma gene function is sufficient for cell cycle re-entry Nature 424 2003 223 228
51. M. Narita, S. Nunez, E. Heard, A.W. Lin, S.A. Hearn, D.L. Spector, G.J. Hannon, S.W. Lowe Rb-mediated heterochromatin formation and silencing of E2F target genes during cellular senescence Cell 113 2003 703 716
52. B. Vogelstein, D. Lane, A.J. Levine Surfing the p53 network Nature 408 2000 307 310
53. C.M. Barton, S.L. Staddon, C.M. Hughes, P.A. Hall, C. O'Sullivan, G. Kloppel, B. Theis, R.C. Russell, J. Neoptolemos, R.C. Williamson Abnormalities of the p53 tumour suppressor gene in human pancreatic cancer Br J Cancer 64 1991 1076 1082
54. C.R. Boschman, S. Stryker, J.K. Reddy, M.S. Rao Expression of p53 protein in precursor lesions and adenocarcinoma of human pancreas Am J Pathol 145 1994 1291 1295
55. J.A. DiGiuseppe, R.H. Hruban, S.N. Goodman, M. Polak, F.M. van den Berg, D.C. Allison, J.L. Cameron, G.J. Offerhaus Overexpression of p53 protein in adenocarcinoma of the pancreas Am J Clin Pathol 101 1994 684 688
56. M.S. Redston, C. Caldas, A.B. Seymour, R.H. Hruban, L. da Costa, C.J. Yeo, S.E. Kern p53 mutations in pancreatic carcinoma and evidence of common involvement of homocopolymer tracts in DNA microdeletions Cancer Res 54 1994 3025 3033
57. G.H. Stein, L.F. Drullinger, A. Soulard, V. Dulic Differential roles for cyclin-dependent kinase inhibitors p21 and p16 in the mechanisms of senescence and differentiation in human fibroblasts Mol Cell Biol 19 1999 2019 2117
58. A.W. Lin, S.W. Lowe Oncogenic ras activates the ARF-p53 pathway to suppress epithelial cell transformation Proc Natl Acad Sci U S A 98 2001 5025 5030
59. G. Ferbeyre, E. de Stanchina, A.W. Lin, E. Querido, M.E. McCurrach, G.J. Hannon, S.W. Lowe Oncogenic ras and p53 cooperate to induce cellular senescence Mol Cell Biol 22 2002 3497 3508
60. C.M. Beausejour, A. Krtolica, F. Galimi, M. Narita, S.W. Lowe, P. Yaswen, J. Campisi Reversal of human cellular senescence roles of the p53 and p16 pathways EMBO J 22 2003 4212 4222
61. A. Noda, Y. Ning, S.F. Venable, O.M. Pereira-Smith, J.R. Smith Cloning of senescent cell-derived inhibitors of DNA synthesis using an expression screen Exp Cell Res 211 1994 90 98
62. A.V. Biankin, J.G. Kench, A.L. Morey, C.S. Lee, S.A. Biankin, D.R. Head, T.B. Hugh, S.M. Henshall, R.L. Sutherland Overexpression of p21(WAF1/CIP1) is an early event in the development of pancreatic intraepithelial neoplasia Cancer Res 61 2001 8830 8837
63. C.J. Sherr The INK4a/ARF network in tumour suppression Nat Rev Mol Cell Biol 2 2001 731 737
64. N.T. van Heek, A.K. Meeker, S.E. Kern, C.J. Yeo, K.D. Lillemoe, J.L. Cameron, G.J. Offerhaus, J.L. Hicks, R.E. Wilentz, M.G. Goggins, A.M. De Marzo, R.H. Hruban, A. Maitra Telomere shortening is nearly universal in pancreatic intraepithelial neoplasia Am J Pathol 161 2002 1541 1547
65. J.W. Shay, O.M. Pereira-Smith, W.E. Wright A role for both RB and p53 in the regulation of human cellular senescence Exp Cell Res 196 1991 33 39
66. A. Smogorzewska, T. de Lange Different telomere damage signaling pathways in human and mouse cells EMBO J 21 2002 4338 4348
67. L. Johnson, K. Mercer, D. Greenbaum, R.T. Bronson, D. Crowley, D.A. Tuveson, T. Jacks Somatic activation of the K-ras oncogene causes early onset lung cancer in mice Nature 410 2001 1111 1116
68. C. Guerra, N. Mijimolle, A. Dhawahir, P. Dubus, M. Barradas, M. Serrano, V. Campuzano, M. Barbacid Tumor induction by an endogenous K-ras oncogene is highly dependent on cellular context Cancer Cell 4 2003 111 120
69. J.A. Benanti, D.A. Galloway Normal human fibroblasts are resistant to RAS-induced senescence Mol Cell Biol 24 2004 2842 2852
70. D.A. Tuveson, A.T. Shaw, N.A. Willis, D.P. Silver, E.L. Jackson, S. Chang, K.L. Mercer, R. Grochow, H. Hock, D. Crowley, S.R. Hingorani, T. Zaks, C. King, M.A. Jacobetz, L. Wang, R.T. Bronson, S.H. Orkin, R.A. DePinho, T. Jacks Endogenous oncogenic K-ras(G12D) stimulates proliferation and widespread neoplastic and developmental defects Cancer Cell 5 2004 375 387
71. P. Kahlem, B. Dorken, C.A. Schmitt Cellular senescence in cancer treatment friend or foe? J Clin Invest 113 2004 169 174
72. G.I. Evan, A.H. Wyllie, C.S. Gilbert, T.D. Littlewood, H. Land, M. Brooks, C.M. Waters, L.Z. Penn, D.C. Hancock Induction of apoptosis in fibroblasts by c-myc protein Cell 69 1992 119 128
73. F.H. Igney, P.H. Krammer Death and anti-death tumour resistance to apoptosis Nat Rev Cancer 2 2002 277 288
74. M.C. Wei, T. Lindsten, V.K. Mootha, S. Weiler, A. Gross, M. Ashiya, C.B. Thompson, S.J. Korsmeyer tBID, a membrane-targeted death ligand, oligomerizes BAK to release cytochrome c Genes Dev 14 2000 2060 2071
75. N. Zamzami, G. Kroemer The mitochondrion in apoptosis how Pandora's box opens Nat Rev Mol Cell Biol 2 2001 67 71
76. X. Luo, I. Budihardjo, H. Zou, C. Slaughter, X. Wang Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors Cell 94 1998 481 490
77. S. Hinz, A. Trauzold, L. Boenicke, C. Sandberg, S. Beckmann, E. Bayer, H. Walczak, H. Kalthoff, H. Ungefroren Bcl-XL protects pancreatic adenocarcinoma cells against CD95- and TRAIL-receptor-mediated apoptosis Oncogene 19 2000 5477 5486
78. A. Trauzold, H. Wermann, A. Arlt, S. Schutze, H. Schafer, S. Oestern, C. Roder, H. Ungefroren, E. Lampe, M. Heinrich, H. Walczak, H. Kalthoff CD95 and TRAIL receptor-mediated activation of protein kinase C and NF-kappaB contributes to apoptosis resistance in ductal pancreatic adenocarcinoma cells Oncogene 20 2001 4258 4269
79. H. Schulze-Bergkamen, P.H. Krammer Apoptosis in cancer--implications for therapy Semin Oncol 31 2004 90 119
80. M.C. Gerhard, R.M. Schmid, G. Hacker Analysis of the cytochrome c-dependent apoptosis apparatus in cells from human pancreatic carcinoma Br J Cancer 86 2002 893 898
81. A.S. Gukovskaya, S.J. Pandol Cell death pathways in pancreatitis and pancreatic cancer Pancreatology 4 2004 567 586
82. M. Kornmann, T. Ishiwata, J. Kleeff, H.G. Beger, M. Korc Fas and Fas-ligand expression in human pancreatic cancer Ann Surg 231 2000 368 379
83. S.M. Ibrahim, J. Ringel, C. Schmidt, B. Ringel, P. Muller, D. Koczan, H.J. Thiesen, M. Lohr Pancreatic adenocarcinoma cell lines show variable susceptibility to TRAIL-mediated cell death Pancreas 23 2001 72 79
84. S. Tsuji, R. Hosotani, S. Yonehara, T. Masui, S.S. Tulachan, S. Nakajima, H. Kobayashi, M. Koizumi, E. Toyoda, D. Ito, K. Kami, T. Mori, K. Fujimoto, R. Doi, M. Imamura Endogenous decoy receptor 3 blocks the growth inhibition signals mediated by Fas ligand in human pancreatic adenocarcinoma Int J Cancer 106 2003 17 25
85. A. Krueger, S. Baumann, P.H. Krammer, S. Kirchhoff FLICE-inhibitory proteins regulators of death receptor-mediated apoptosis Mol Cell Biol 21 2001 8247 8254
86. A. Elnemr, T. Ohta, A. Yachie, M. Kayahara, H. Kitagawa, T. Fujimura, I. Ninomiya, S. Fushida, G.I. Nishimura, K. Shimizu, K. Miwa Human pancreatic cancer cells disable function of Fas receptors at several levels in Fas signal transduction pathway Int J Oncol 18 2001 311 316
87. A. Trauzold, S. Schmiedel, C. Roder, C. Tams, M. Christgen, S. Oestern, A. Arlt, S. Westphal, M. Kapischke, H. Ungefroren, H. Kalthoff Multiple and synergistic deregulations of apoptosis-controlling genes in pancreatic carcinoma cells Br J Cancer 89 2003 1714 1721
88. H. Ungefroren, M.L. Kruse, A. Trauzold, S. Roeschmann, C. Roeder, A. Arlt, D. Henne-Bruns, H. Kalthoff FAP-1 in pancreatic cancer cells functional and mechanistic studies on its inhibitory role in CD95-mediated apoptosis J Cell Sci 114 2001 2735 2746
89. A. Trauzold, C. Roder, B. Sipos, K. Karsten, A. Arlt, P. Jiang, J.I. Martin-Subero, D. Siegmund, S. Muerkoster, L. Pagerols Raluy, R. Siebert, H. Wajant, H. Kalthoff CD95 and TRAF2 promote invasiveness of pancreatic cancer cells FASEB J 19 2005 620 622
90. D. Campani, I. Esposito, U. Boggi, D. Cecchetti, M. Menicagli, F. De Negri, L. Colizzi, M. Del Chiaro, F. Mosca, G. Fornaciari, G. Bevilacqua Bcl-2 expression in pancreas development and pancreatic cancer progression J Pathol 194 2001 444 450
91. J.D. Evans, P.A. Cornford, A. Dodson, W. Greenhalf, C.S. Foster, J.P. Neoptolemos Detailed tissue expression of bcl-2, bax, bak and bcl-x in the normal human pancreas and in chronic pancreatitis, ampullary and pancreatic ductal adenocarcinomas Pancreatology 1 2001 254 262
92. Q.L. Deveraux, J.C. Reed IAP family proteins--suppressors of apoptosis Genes Dev 13 1999 239 252
93. K. Satoh, K. Kaneko, M. Hirota, A. Masamune, A. Satoh, T. Shimosegawa Expression of survivin is correlated with cancer cell apoptosis and is involved in the development of human pancreatic duct cell tumors Cancer 92 2001 271 278
94. A.I. Sarela, C.S. Verbeke, J. Ramsdale, C.L. Davies, A.F. Markham, P.J. Guillou Expression of survivin, a novel inhibitor of apoptosis and cell cycle regulatory protein, in pancreatic adenocarcinoma Br J Cancer 86 2002 886 892
95. M. Karin, Y. Cao, F.R. Greten, Z.W. Li NF-kappaB in cancer from innocent bystander to major culprit Nat Rev Cancer 2 2002 301 310
96. W. Wang, J.L. Abbruzzese, D.B. Evans, L. Larry, K.R. Cleary, P.J. Chiao The nuclear factor-kappa B RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells Clin Cancer Res 5 1999 119 127
97. S. Liptay, C.K. Weber, L. Ludwig, M. Wagner, G. Adler, R.M. Schmid Mitogenic and antiapoptotic role of constitutive NF-kappaB/Rel activity in pancreatic cancer Int J Cancer 105 2003 735 746
98. A. Arlt, J. Vorndamm, M. Breitenbroich, U.R. Folsch, H. Kalthoff, W.E. Schmidt, H. Schafer Inhibition of NF-kappaB sensitizes human pancreatic carcinoma cells to apoptosis induced by etoposide (VP16) or doxorubicin Oncogene 20 2001 859 868
99. R.P. Thomas, B.J. Farrow, S. Kim, M.J. May, M.R. Hellmich, B.M. Evers Selective targeting of the nuclear factor-kappaB pathway enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated pancreatic cancer cell death Surgery 132 2002 127 134
100. S. Muerkoster, A. Arlt, M. Witt, A. Gehrz, S. Haye, C. March, F. Grohmann, K. Wegehenkel, H. Kalthoff, U.R. Folsch, H. Schafer Usage of the NF-kappaB inhibitor sulfasalazine as sensitizing agent in combined chemotherapy of pancreatic cancer Int J Cancer 104 2003 469 476
101. T. Sato, H. Odagiri, S.K. Ikenaga, M. Maruyama, M. Sasaki Chemosensitivity of human pancreatic carcinoma cells is enhanced by IkappaBalpha super-repressor Cancer Sci 94 2003 467 472
102. S. Fujioka, G.M. Sclabas, C. Schmidt, J. Niu, W.A. Frederick, Q.G. Dong, J.L. Abbruzzese, D.B. Evans, C. Baker, P.J. Chiao Inhibition of constitutive NF-kappa B activity by I kappa B alpha M suppresses tumorigenesis Oncogene 22 2003 1365 1370
103. S. Fujioka, G.M. Sclabas, C. Schmidt, W.A. Frederick, Q.G. Dong, J.L. Abbruzzese, D.B. Evans, C. Baker, P.J. Chiao Function of nuclear factor kappaB in pancreatic cancer metastasis Clin Cancer Res 9 2003 346 354
104. J.S. Fridman, S.W. Lowe Control of apoptosis by p53 Oncogene 22 2003 9030 9040
105. M.C. Moroni, E.S. Hickman, E.L. Denchi, G. Caprara, E. Colli, F. Cecconi, H. Muller, K. Helin Apaf-1 is a transcriptional target for E2F and p53 Nat Cell Biol 3 2001 552 558
106. Z. Nahle, J. Polakoff, R.V. Davuluri, M.E. McCurrach, M.D. Jacobson, M. Narita, M.Q. Zhang, Y. Lazebnik, D. Bar-Sagi, S.W. Lowe Direct coupling of the cell cycle and cell death machinery by E2F Nat Cell Biol 4 2002 859 864
107. T. Hershko, D. Ginsberg Up-regulation of Bcl-2 homology 3 (BH3)-only proteins by E2F1 mediates apoptosis J Biol Chem 279 2004 8627 8634
108. M.J. Elliott, M.R. Farmer, C. Atienza Jr, A. Stilwell, Y.B. Dong, H.L. Yang, S.L. Wong, K.M. McMasters E2F-1 gene therapy induces apoptosis and increases chemosensitivity in human pancreatic carcinoma cells Tumour Biol 23 2002 76 86
109. T. Plath, M. Peters, K. Detjen, M. Welzel, Z. von Marschall, C. Radke, B. Wiedenmann, S. Rosewicz Overexpression of pRB in human pancreatic carcinoma cells function in chemotherapy-induced apoptosis J Natl Cancer Inst 94 2002 129 142
110. H. Okada, T.W. Mak Pathways of apoptotic and non-apoptotic death in tumour cells Nat Rev Cancer 4 2004 592 603
111. D.M. Ornitz, R.E. Hammer, A. Messing, R.D. Palmiter, R.L. Brinster Pancreatic neoplasia induced by SV40 T-antigen expression in acinar cells of transgenic mice Science 238 1987 188 193
112. C.J. Quaife, C.A. Pinkert, D.M. Ornitz, R.D. Palmiter, R.L. Brinster Pancreatic neoplasia induced by ras expression in acinar cells of transgenic mice Cell 48 1987 1023 1034
113. E.P. Sandgren, N.C. Luetteke, R.D. Palmiter, R.L. Brinster, D.C. Lee Overexpression of TGF alpha in transgenic mice induction of epithelial hyperplasia, pancreatic metaplasia, and carcinoma of the breast Cell 61 1990 1121 1135
114. E.P. Sandgren, C.J. Quaife, A.G. Paulovich, R.D. Palmiter, R.L. Brinster Pancreatic tumor pathogenesis reflects the causative genetic lesion Proc Natl Acad Sci U S A 88 1991 93 97
115. M. Wagner, H. Luhrs, G. Kloppel, G. Adler, R.M. Schmid Malignant transformation of duct-like cells originating from acini in transforming growth factor transgenic mice Gastroenterology 115 1998 1254 1262
116. M. Wagner, F.R. Greten, C.K. Weber, S. Koschnick, T. Mattfeldt, W. Deppert, H. Kern, G. Adler, R.M. Schmid A murine tumor progression model for pancreatic cancer recapitulating the genetic alterations of the human disease Genes Dev 15 2001 286 293
117. N. Bardeesy, J. Morgan, M. Sinha, S. Signoretti, S. Srivastava, M. Loda, G. Merlino, R.A. DePinho Obligate roles for p16(Ink4a) and p19(Arf)-p53 in the suppression of murine pancreatic neoplasia Mol Cell Biol 22 2002 635 643
118. F.H. Brembeck, F.S. Schreiber, T.B. Deramaudt, L. Craig, B. Rhoades, G. Swain, P. Grippo, D.A. Stoffers, D.G. Silberg, A.K. Rustgi The mutant K-ras oncogene causes pancreatic periductal lymphocytic infiltration and gastric mucous neck cell hyperplasia in transgenic mice Cancer Res 63 2003 2005 2009
119. P.J. Grippo, P.S. Nowlin, M.J. Demeure, D.S. Longnecker, E.P. Sandgren Preinvasive pancreatic neoplasia of ductal phenotype induced by acinar cell targeting of mutant Kras in transgenic mice Cancer Res 63 2003 2016 2019
120. L.C. Murtaugh, D.A. Melton Genes, signals, and lineages in pancreas development Annu Rev Cell Dev Biol 19 2003 71 89
121. H. Edlund Pancreatic organogenesis--developmental mechanisms and implications for therapy Nat Rev Genet 3 2002 524 532
122. S.K. Kim, M. Hebrok Intercellular signals regulating pancreas development and function Genes Dev 15 2001 111 127
123. U. Ahlgren, J. Jonsson, H. Edlund The morphogenesis of the pancreatic mesenchyme is uncoupled from that of the pancreatic epithelium in IPF1/PDX1-deficient mice Development 122 1996 1409 1416
124. M.F. Offield, T.L. Jetton, P.A. Labosky, M. Ray, R.W. Stein, M.A. Magnuson, B.L. Hogan, C.V. Wright PDX-1 is required for pancreatic outgrowth and differentiation of the rostral duodenum Development 122 1996 983 995
125. A.M. Holland, M.A. Hale, H. Kagami, R.E. Hammer, R.J. MacDonald Experimental control of pancreatic development and maintenance Proc Natl Acad Sci U S A 99 2002 12236 12241
126. S.Y. Song, M. Gannon, M.K. Washington, C.R. Scoggins, I.M. Meszoely, J.R. Goldenring, C.R. Marino, E.P. Sandgren, R.J. Coffey Jr, C.V. Wright, S.D. Leach Expansion of Pdx1-expressing pancreatic epithelium and islet neogenesis in transgenic mice overexpressing transforming growth factor alpha Gastroenterology 117 1999 1416 1426
127. Y. Kawaguchi, B. Cooper, M. Gannon, M. Ray, R.J. MacDonald, C.V. Wright The role of the transcriptional regulator Ptf1a in converting intestinal to pancreatic progenitors Nat Genet 32 2002 128 134
128. X. Luo, D.M. Shin, X. Wang, S.F. Konieczny, S. Muallem Aberrant localization of intracellular organelles, Ca2+ signaling and exocytosis in Mist1 null mice J Biol Chem 280 2005 12668 12675
129. L. Zhu, T. Tran, J.M. Rukstalis, P. Sun, B. Damsz, S.F. Konieczny Inhibition of Mist1 homodimer formation induces pancreatic acinar-to-ductal metaplasia Mol Cell Biol 24 2004 2673 2681
130. S.R. Hingorani, E.F. Petricoin, A. Maitra, V. Rajapakse, C. King, M.A. Jacobetz, S. Ross, T.P. Conrads, T.D. Veenstra, B.A. Hitt, Y. Kawaguchi, D. Johann, L.A. Liotta, H.C. Crawford, M.E. Putt, T. Jacks, C.V. Wright, R.H. Hruban, A.M. Lowy, D.A. Tuveson Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse Cancer Cell 4 2003 437 450
131. A.J. Aguirre, N. Bardeesy, M. Sinha, L. Lopez, D.A. Tuveson, J. Horner, M.S. Redston, R.A. DePinho Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma Genes Dev 17 2003 3112 3126
132. Y. Miyamoto, A. Maitra, B. Ghosh, U. Zechner, P. Argani, C.A. Iacobuzio-Donahue, V. Sriuranpong, T. Iso, I.M. Meszoely, M.S. Wolfe, R.H. Hruban, D.W. Ball, R.M. Schmid, S.D. Leach Notch mediates TGF alpha-induced changes in epithelial differentiation during pancreatic tumorigenesis Cancer Cell 3 2003 565 576
133. M. Al-Hajj, M.F. Clarke Self-renewal and solid tumor stem cells Oncogene 23 2004 7274 7282
134. R. Pardal, M.F. Clarke, S.J. Morrison Applying the principles of stem-cell biology to cancer Nat Rev Cancer 3 2003 895 902
135. S.P. Thayer, M.P. di Magliano, P.W. Heiser, C.M. Nielsen, D.J. Roberts, G.Y. Lauwers, Y.P. Qi, S. Gysin, C. Fernandez-del Castillo, V. Yajnik, B. Antoniu, M. McMahon, A.L. Warshaw, M. Hebrok Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis Nature 425 2003 851 856
136. D.M. Berman, S.S. Karhadkar, A. Maitra, R. Montes De Oca, M.R. Gerstenblith, K. Briggs, A.R. Parker, Y. Shimada, J.R. Eshleman, D.N. Watkins, P.A. Beachy Widespread requirement for Hedgehog ligand stimulation in growth of digestive tract tumours Nature 425 2003 846 851
137. B.C. Lewis, D.S. Klimstra, H.E. Varmus The c-myc and PyMT oncogenes induce different tumor types in a somatic mouse model for pancreatic cancer Genes Dev 17 2003 3127 3138
138. S.F. Sener, A. Fremgen, H.R. Menck, D.P. Winchester Pancreatic cancer a report of treatment and survival trends for 100,313 patients diagnosed from 1985-1995, using the National Cancer Database J Am Coll Surg 189 1999 1 7
139. A. Richter, M. Niedergethmann, J.W. Sturm, D. Lorenz, S. Post, M. Trede Long-term results of partial pancreaticoduodenectomy for ductal adenocarcinoma of the pancreatic head 25-year experience World J Surg 27 2003 324 329
140. M. Wagner, C. Redaelli, M. Lietz, C.A. Seiler, H. Friess, M.W. Buchler Curative resection is the single most important factor determining outcome in patients with pancreatic adenocarcinoma Br J Surg 91 2004 586 594
141. J.P. Neoptolemos, D.D. Stocken, J.A. Dunn, J. Almond, H.G. Beger, P. Pederzoli, C. Bassi, C. Dervenis, L. Fernandez-Cruz, F. Lacaine, J. Buckels, M. Deakin, F.A. Adab, R. Sutton, C. Imrie, I. Ihse, T. Tihanyi, A. Olah, S. Pedrazzoli, D. Spooner, D.J. Kerr, H. Friess, M.W. Buchler Influence of resection margins on survival for patients with pancreatic cancer treated by adjuvant chemoradiation and/or chemotherapy in the ESPAC-1 randomized controlled trial Ann Surg 234 2001 758 768
142. J.P. Neoptolemos, D.D. Stocken, H. Friess, C. Bassi, J.A. Dunn, H. Hickey, H. Beger, L. Fernandez-Cruz, C. Dervenis, F. Lacaine, M. Falconi, P. Pederzoli, A. Pap, D. Spooner, D.J. Kerr, M.W. Buchler A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer N Engl J Med 350 2004 1200 1210
143. V.J. Picozzi, R.A. Kozarek, L.W. Traverso Interferon-based adjuvant chemoradiation therapy after pancreaticoduodenectomy for pancreatic adenocarcinoma Am J Surg 185 2003 476 480
144. J.P. Hoffman, S. Lipsitz, T. Pisansky, J.L. Weese, L. Solin, A.B. Benson III Phase II trial of preoperative radiation therapy and chemotherapy for patients with localized, resectable adenocarcinoma of the pancreas an Eastern Cooperative Oncology Group Study J Clin Oncol 16 1998 317 323
145. C.P. Raut, D.B. Evans, C.H. Crane, P.W. Pisters, R.A. Wolff Neoadjuvant therapy for resectable pancreatic cancer Surg Oncol Clin North Am 13 2004 639 661 ix
146. Gastrointestinal Tumor Study Group Treatment of locally unresectable carcinoma of the pancreas. comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone J Natl Cancer Inst 80 1988 751 755
147. D.J. Klaassen, J.M. MacIntyre, G.E. Catton, P.F. Engstrom, C.G. Moertel Treatment of locally unresectable cancer of the stomach and pancreas a randomized comparison of 5-fluorouracil alone with radiation plus concurrent and maintenance 5-fluorouracil--an Eastern Cooperative Oncology Group study J Clin Oncol 3 1985 373 378
148. J.J. Hazel, M.P. Thirlwell, M. Huggins, A. Maksymiuk, J.K. MacFarlane Multi-drug chemotherapy with and without radiation for carcinoma of the stomach and pancreas a prospective randomized trial J Can Assoc Radiol 32 1981 164 165
149. N.C. Balci, R.C. Semelka Radiologic diagnosis and staging of pancreatic ductal adenocarcinoma Eur J Radiol 38 2001 105 112
150. C. Kollmannsberger, H.D. Peters, U. Fink Chemotherapy in advanced pancreatic adenocarcinoma Cancer Treat Rev 24 1998 133 156
151. S.A. Cullinan, C.G. Moertel, T.R. Fleming, J.R. Rubin, J.E. Krook, L.K. Everson, H.E. Windschitl, D.I. Twito, R.F. Marschke, J.F. Foley A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma. Fluorouracil vs fluorouracil and doxorubicin vs fluorouracil, doxorubicin, and mitomycin JAMA 253 1985 2061 2067
152. J. Carmichael, U. Fink, R.C. Russell, M.F. Spittle, A.L. Harris, G. Spiessi, J. Blatter Phase II study of gemcitabine in patients with advanced pancreatic cancer Br J Cancer 73 1996 101 105
153. H.A. Burris III, M.J. Moore, J. Andersen, M.R. Green, M.L. Rothenberg, M.R. Modiano, M.C. Cripps, R.K. Portenoy, A.M. Storniolo, P. Tarassoff, R. Nelson, F.A. Dorr, C.D. Stephens, D.D. Von Hoff Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer a randomized trial J Clin Oncol 15 1997 2403 2413
154. D. Kelsen, C. Hudis, D. Niedzwiecki, J. Dougherty, E. Casper, J. Botet, V. Vinciguerra, R. Rosenbluth A phase III comparison trial of streptozotocin, mitomycin, and 5-fluorouracil with cisplatin, cytosine arabinoside, and caffeine in patients with advanced pancreatic carcinoma Cancer 68 1991 965 969
155. N. Maisey, I. Chau, D. Cunningham, A. Norman, M. Seymour, T. Hickish, T. Iveson, M. O'Brien, N. Tebbutt, A. Harrington, M. Hill Multicenter randomized phase III trial comparing protracted venous infusion (PVI) fluorouracil (5-FU) with PVI 5-FU plus mitomycin in inoperable pancreatic cancer J Clin Oncol 20 2002 3130 3136
156. S. Ward, E. Morris, N. Bansback, N. Calvert, A. Crellin, D. Forman, M. Larvin, D. Radstone A rapid and systematic review of the clinical effectiveness and cost-effectiveness of gemcitabine for the treatment of pancreatic cancer Health Technol Assess 5 2001 1 70
157. J.D. Berlin, P. Catalano, J.P. Thomas, J.W. Kugler, D.G. Haller, A.B. Benson III Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma Eastern Cooperative Oncology Group Trial E2297 J Clin Oncol 20 2002 3270 3275
158. V. Hess, M. Salzberg, M. Borner, R. Morant, A.D. Roth, C. Ludwig, R. Herrmann Combining capecitabine and gemcitabine in patients with advanced pancreatic carcinoma a phase I/II trial J Clin Oncol 21 2003 66 68
159. S. Okada, Y. Sakata, S. Matsuno, M. Kurihara, Y. Sasaki, Y. Ohashi, T. Taguchi Cooperative Group of Docetaxel for Pancreatic Cancer in Japan Phase II study of docetaxel in patients with metastatic pancreatic cancer a Japanese cooperative study Br J Cancer 80 1999 438 443
160. R. Lenzi, S. Yalcin, D.B. Evans, J.L. Abbruzzese Phase II study of docetaxel in patients with pancreatic cancer previously untreated with cytotoxic chemotherapy Cancer Invest 20 2002 464 472
161. N. Androulakis, C. Kourousis, M.A. Dimopoulos, G. Samelis, S. Kakolyris, N. Tsavaris, K. Genatas, G. Aravantinos, C. Papadimitriou, S. Karabekios, G.P. Stathopoulos, V. Georgoulias Treatment of pancreatic cancer with docetaxel and granulocyte colony-stimulating factor a multicenter phase II study J Clin Oncol 17 1999 1779 1785
162. P. Rougier, A. Adenis, M. Ducreux, M. de Forni, J. Bonneterre, M. Dembak, P. Clouet, A. Lebecq, P. Baille, F. Lefresne-Soulas, C. Blanc, J.P. Armand A phase II study docetaxel as first-line chemotherapy for advanced pancreatic adenocarcinoma Eur J Cancer 36 2000 1016 1025
163. R. Veitia, M.C. Bissery, C. Martinez, A. Fellous Tau expression in model adenocarcinomas correlates with docetaxel sensitivity in tumour-bearing mice Br J Cancer 78 1998 871 877
164. D.R. Fogelman, J. Chen, J.A. Chabot, J.D. Allendorf, B.A. Schrope, R.D. Ennis, S.M. Schreibman, R.L. Fine The evolution of adjuvant and neoadjuvant chemotherapy and radiation for advanced pancreatic cancer from 5-fluorouracil to GTX Surg Oncol Clin North Am 13 2004 711 735 x
165. C.M. Rocha Lima, M.R. Green, R. Rotche, W.H. Miller Jr, G.M. Jeffrey, L.A. Cisar, A. Morganti, N. Orlando, G. Gruia, L.L. Miller Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate J Clin Oncol 22 2004 3776 3783
166. E.M. O'Reilly, G.K. Abou-Alfa, R. Letourneau, W.G. Harker, M. Modiano, H. Hurwitz, N.S. Tchekmedyian, J. Ackerman, R.L. De Jager, S.G. Eckardt A randomized phase III trial of DX-8951f (exatecan mesylate; DX) and gemcitabine (GEM) vs. gemcitabine alone in advanced pancreatic cancer (APC) (abstr 4006) Proc Am Soc Clin Oncol 23 2004
167. P. Cheverton, H. Friess, C. Andras, T. Salek, C. Geddes, G. Bodoky, J. Valle, Y. Humblet Phase III results of exatecan (DX-8951f) versus gemcitabine (Gem) in chemotherapy-naïve patients with advanced pancreatic cancer (APC) (abstr 4005) Proc Am Soc Clin Oncol 23 2004
168. B.J. Braakhuis, V.W. Ruiz van Haperen, E. Boven, G. Veerman, G.J. Peters Schedule-dependent antitumor effect of gemcitabine in in vivo model system Semin Oncol 22 1995 42 46
169. M. Tempero, W. Plunkett, V. Ruiz Van Haperen, J. Hainsworth, H. Hochster, R. Lenzi, J. Abbruzzese Randomized phase II comparison of dose-intense gemcitabine thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma J Clin Oncol 21 2003 3402 3408
170. G. Colucci, F. Giuliani, V. Gebbia, M. Biglietto, P. Rabitti, G. Uomo, S. Cigolari, A. Testa, E. Maiello, M. Lopez Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma a prospective, randomized phase III study of the Gruppo Oncologia dell'Italia Meridionale Cancer 94 2002 902 910
171. V. Heinemann, D. Quietzsch, F. Gieseler, M. Gonnermann, H. Schonekas, A. Rost, H. Neuhaus, C. Haag, C. Stoffregen, M. Clemens A phase III trial comparing gemcitabine plus cisplatin vs. gemcitabine alone in advanced pancreatic carcinoma (abstr 1003) Proc Am Soc Clin Oncol 22 2003
172. C. Louvet, R. Labianca, P. Hammel, G. Lledo, Braud F. de, T. Andre, M. Cantore, M. Ducreux, A. Zaniboni, Gramont A. De GemOx (gemcitabine + oxaliplatin) versus Gem (gemcitabine) in non resectable pancreatic adenocarcinoma final results of the GERCOR/GISCAD Intergroup phase III (abstr 4008) Proc Am Soc Clin Oncol 23 2004
173. M. Dong, Y. Nio, K.J. Guo, K. Tamura, Y.L. Tian, Y.T. Dong Epidermal growth factor and its receptor as prognostic indicators in Chinese patients with pancreatic cancer Anticancer Res 18 1998 4613 4619
174. H.Q. Xiong, A. Rosenberg, A. LoBuglio, W. Schmidt, R.A. Wolff, J. Deutsch, M. Needle, J.L. Abbruzzese Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer a multicenter phase II trial J Clin Oncol 22 2004 2610 2616
175. B.W. Porterfield, T. Dragovich, A. Patnaik, E. Rowinsky, M. Huberman, T. Clinebell, M. Hamilton, A. Zitelli, P. Nadler, D. Wood Erlotinib + gemcitabine in patients with unresectable pancreatic carcinoma results from a phase IB trial (abstr 4110) Proc Am Soc Clin Oncol 23 2004 339
176. Moore MJ, Goldstein D, Hamm J, Kotecha J, Gallinger S, Au HJ, Nomikos D, Ding K, Ptaszynski M, Parulekar W. Erlotinib improves survival when added to gemcitabine in patients with advanced pancreatic cancer. A phase III trial of the National Cancer Institute of Canada Clinical Trials Group [NCIC-CTG] (abstr 77). American Society of Clinical Oncology Gastrointestinal Cancers Symposium, Hollywood, FL, 2005.
177. H. Hurwitz, L. Fehrenbacher, W. Novotny, T. Cartwright, J. Hainsworth, W. Heim, J. Berlin, A. Baron, S. Griffing, E. Holmgren, N. Ferrara, G. Fyfe, B. Rogers, R. Ross, F. Kabbinavar Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N Engl J Med 350 2004 2335 2342
178. H.L. Kindler, G. Friberg, W.M. Stadler, D.A. Singh, G. Locker, S. Nattam, M. Kozloff, K. Kasza, E.E. Vokes Bevacizumab (B) plus gemcitabine (G) in patient (pts) with advanced pancreatic cancer (PC) updated results of a multi-center phase II trial (abstr 4009) Proc Am Soc Clin Oncol 23 2004 314
179. D. Wei, L. Wang, Y. He, H.Q. Xiong, J.L. Abbruzzese, K. Xie Celecoxib inhibits vascular endothelial growth factor expression in and reduces angiogenesis and metastasis of human pancreatic cancer via suppression of Sp1 transcription factor activity Cancer Res 64 2004 2030 2038
180. T. Koshiba, R. Hosotani, M. Wada, Y. Miyamoto, K. Fujimoto, J.U. Lee, R. Doi, S. Arii, M. Imamura Involvement of matrix metalloproteinase-2 activity in invasion and metastasis of pancreatic carcinoma Cancer 82 1998 642 650
181. S.R. Bramhall, A. Rosemurgy, P.D. Brown, C. Bowry, J.A. Buckels Marimastat as first-line therapy for patients with unresectable pancreatic cancer a randomized trial J Clin Oncol 19 2001 3447 3455
182. S.R. Bramhall, J. Schulz, J. Nemunaitis, P.D. Brown, M. Baillet, J.A. Buckels A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer Br J Cancer 87 2002 161 167
183. M.J. Moore, J. Hamm, J. Dancey, P.D. Eisenberg, M. Dagenais, A. Fields, K. Hagan, B. Greenberg, B. Colwell, B. Zee, D. Tu, J. Ottaway, R. Humphrey, L. Seymour Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas a phase III trial of the National Cancer Institute of Canada Clinical Trials Group J Clin Oncol 21 2003 3296 3302
184. D.A. Richards, H.L. Kindler, H. Oettle, R. Ramanathan, Laethem J.L. Van, M. Peeters, M. Fuchs, W. John, M. Arning, Hoff D. Von A randomized phase III study comparing gemcitabine + pemetrexed versus gemcitabine in patients with locally advanced and metastatic pancreas cancer (abstr 4007) Proc Am Soc Clin Oncol 23 2004
185. L.H. Cohen, E. Pieterman, R.E. van Leeuwen, M. Overhand, B.E. Burm, G.A. van der Marel, J.H. van Boom Inhibitors of prenylation of Ras and other G-proteins and their application as therapeutics Biochem Pharmacol 60 2000 1061 1068
186. E. Van Cutsem, H. van de Velde, P. Karasek, H. Oettle, W.L. Vervenne, A. Szawlowski, P. Schoffski, S. Post, C. Verslype, H. Neumann, H. Safran, Y. Humblet, J. Perez Ruixo, Y. Ma, D.D. Von Hoff Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer J Clin Oncol 22 2004 1430 1438
187. C. Frey, P. Twomey, R. Keehn, D. Elliott, G. Higgins Randomized study of 5-FU and CCNU in pancreatic cancer report of the Veterans Administration Surgical Adjuvant Cancer Chemotherapy Study Group Cancer 47 1981 27 31
188. B. Glimelius, K. Hoffman, P.O. Sjoden, G. Jacobsson, H. Sellstrom, L.K. Enander, T. Linne, C. Svensson Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer Ann Oncol 7 1996 593 600
189. K.R. Palmer, M. Kerr, G. Knowles, A. Cull, D.C. Carter, R.C. Leonard Chemotherapy prolongs survival in inoperable pancreatic carcinoma Br J Surg 81 1994 882 885
190. M.C. Fung, H. Ishiguro, S. Takayama, T. Morizane, S. Adachi, T. Sakata Survival benefit of chemotherapy treatment in advanced pancreatic cancer a meta-analysis (abstr 1155) Proc Am Soc Clin Oncol 22 2003
191. K.D. Lillemoe, J.L. Cameron, H.S. Kaufman, C.J. Yeo, H.A. Pitt, P.K. Sauter Chemical splanchnicectomy in patients with unresectable pancreatic cancer. A prospective randomized trial Ann Surg 217 1993 447 455 discussion 456-457
192. G.Y. Wong, D.R. Schroeder, P.E. Carns, J.L. Wilson, D.P. Martin, M.O. Kinney, C.B. Mantilla, D.O. Warner Effect of neurolytic celiac plexus block on pain relief, quality of life, and survival in patients with unresectable pancreatic cancer a randomized controlled trial JAMA 291 2004 1092 1099
193. A.A. Khorana, R.L. Fine Pancreatic cancer and thromboembolic disease Lancet Oncol 5 2004 655 663
194. F. Icli, H. Akbulut, G. Utkan, D. Dincol, A. Isikdogan, A. Demirkazik, H. Onur, F. Cay, A. Buyukcelik, B. Yalcin Low molecular weight heparin (LMWH) increases the efficacy of cisplatinum plus gemcitabine combination in advanced pancreatic cancer (abstr 1149) Proc Am Soc Clin Oncol 22 2003